“r.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
(Reuters) – AstraZeneca Plc said Monday that it had begun recruiting adults for a 30,000 U.S.-funded subject complex in its high-level COVID-19 candidate vaccine.
Trial participants will get two doses of the experimental vaccine, called AZD1222, 4 weeks apart, or a placebo, the company said.
The trial is conducted from the US government’s Operation Warp Speed program.Usa, whose objective is to promote the development, manufacture and distribution of vaccines and remedies for COVID-19.
U.S. President Donald Trump has said a vaccine opposed to the new coronavirus could be available before the November 3 presidential election, much earlier than top experts predict.
AstraZeneca, which is preparing its vaccine in collaboration with researchers at the University of Oxford, and Pfizer Inc.with their spouse BioNTech SE said they may be aware until October of the U.S. emergency use authorization or approval.Hus Of their respective vaccines.
AZD1222 is already undergoing complex clinical trials in Britain, Brazil and South Africa, with more trials planned in Japan and Russia.The trials, such as the US Phase III study, have been in the process of being tested.They aim to recruit up to 50,000 participants worldwide.
The U.S. trial will compare whether the vaccine can prevent COVID-19 infection or prevent the disease from becoming serious, the National Institutes of Health said in https://www.nih.gov/news-events/news-releases./ phase -3-clinical trials-starts-us-astrazeneca-covid-19-candidate-vaccine-.
It will also assess whether the vaccine can lead to emergency visits to the branch due to COVID-19.
(Reporting via Manojna Maddipatla in Bengaluru; Editing via Bill Berkrot)